Exelixis, Inc. (NASDAQ:EXEL) Position Lowered by C WorldWide Group Holding A S
C WorldWide Group Holding A S lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 46.9% during the second quarter, Holdings Channel reports. The fund owned 295,175 shares of the biotechnology company’s stock after selling 260,283 shares during the period. C WorldWide Group Holding A S’s holdings in Exelixis were worth $7,270,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Fortaleza Asset Management Inc. purchased a new stake in Exelixis during the first quarter worth approximately $106,000. First Quadrant L P CA purchased a new stake in Exelixis during the second quarter worth approximately $144,000. Meeder Asset Management Inc. purchased a new stake in Exelixis during the first quarter worth approximately $170,000. Atlantic Trust Group LLC purchased a new stake in Exelixis during the first quarter worth approximately $216,000. Finally, Klingenstein Fields & Co. LLC purchased a new stake in Exelixis during the first quarter worth approximately $217,000. Hedge funds and other institutional investors own 80.19% of the company’s stock.
Exelixis, Inc. (EXEL) opened at 26.45 on Friday. Exelixis, Inc. has a 12 month low of $10.04 and a 12 month high of $28.45. The company has a market cap of $7.77 billion, a P/E ratio of 133.59 and a beta of 1.89. The company’s 50-day moving average is $26.05 and its 200-day moving average is $22.23.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.02. The company had revenue of $99.01 million for the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a net margin of 18.20% and a return on equity of 80.43%. Exelixis’s revenue was up 173.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.15) EPS. On average, equities research analysts expect that Exelixis, Inc. will post $0.26 EPS for the current fiscal year.
A number of research firms have recently commented on EXEL. Piper Jaffray Companies reiterated a “buy” rating and set a $29.00 price target on shares of Exelixis in a report on Thursday, August 3rd. Cann reiterated a “hold” rating on shares of Exelixis in a report on Wednesday, April 19th. Zacks Investment Research cut shares of Exelixis from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 28th. Deutsche Bank AG cut shares of Exelixis from a “buy” rating to a “hold” rating and increased their price target for the company from $26.00 to $29.00 in a report on Thursday, August 3rd. Finally, Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a report on Thursday. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $25.57.
In other Exelixis news, Director Carl B. Feldbaum sold 32,988 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $21.58, for a total transaction of $711,881.04. Following the sale, the director now owns 52,721 shares of the company’s stock, valued at approximately $1,137,719.18. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Patrick J. Haley sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total transaction of $92,300.00. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by insiders.
Exelixis Company Profile
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.